Merck, Inc.
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT06104449
- Locations
- 🇯🇵
Yokohama City University Medical Center ( Site 0002), Yokohama, Kanagawa, Japan
🇯🇵National Cancer Center Hospital East ( Site 0001), Kashiwa, Chiba, Japan
🇯🇵Toho University Sakura Medical Center ( Site 0003), Sakura, Chiba, Japan
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 144
- Registration Number
- NCT06099782
- Locations
- 🇺🇸
Russell Medical ( Site 0160), Alexander City, Alabama, United States
🇺🇸Alaska Oncology and Hematology ( Site 0121), Anchorage, Alaska, United States
🇺🇸Highlands Oncology Group-Research Department ( Site 0133), Springdale, Arkansas, United States
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06079879
- Locations
- 🇨🇳
Anhui Provincial Hospital ( Site 3513), Hefei, Anhui, China
🇨🇳Peking University Third Hospital-Hematology ( Site 3502), Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital Of Fujian Medical University ( Site 3525), Quanzhou, Fujian, China
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 868
- Registration Number
- NCT06077760
- Locations
- 🇺🇸
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0013), Orlando, Florida, United States
🇺🇸Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0012), Marietta, Georgia, United States
🇺🇸The University of Louisville, James Graham Brown Cancer Center ( Site 0037), Louisville, Kentucky, United States
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 556
- Registration Number
- NCT06074588
- Locations
- 🇧🇷
A. C. Camargo Cancer Center-CAPEC ( Site 0442), Sao Paulo, Brazil
🇧🇷Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0446), Sao Paulo, Brazil
🇨🇱K2 Oncology ( Site 0514), Santiago, Region M. De Santiago, Chile
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1020
- Registration Number
- NCT06052059
- Locations
- 🇺🇸
Lenox Hill Hospital ( Site 0128), New York, New York, United States
🇺🇸MEDICAL COLLEGE OF WISCONSIN ( Site 0141), Milwaukee, Wisconsin, United States
🇦🇺Monash Health-Gastroenterology ( Site 2505), Clayton, Victoria, Australia
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT06052566
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0005), Miami, Florida, United States
🇺🇸American Research Corporation ( Site 0002), San Antonio, Texas, United States
🇺🇸Advanced Pharma CR, LLC ( Site 0001), Miami, Florida, United States
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06049212
- Locations
- 🇯🇵
National Hospital Organization Shikoku Cancer Center ( Site 0008), Matsuyama, Ehime, Japan
🇯🇵Aichi Cancer Center Hospital ( Site 0006), Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital East ( Site 0002), Kashiwa, Chiba, Japan
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 350
- Registration Number
- NCT06045507
- Locations
- 🇺🇸
University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0041), Pittsburgh, Pennsylvania, United States
🇿🇦Wits RHI-Wits RHI Ward 21 Clinical Research site ( Site 0027), Johannesburg, Gauteng, South Africa
🇿🇦Helen Joseph Hospital ( Site 0024), Johannesburg, Gauteng, South Africa
A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 19
- Registration Number
- NCT06041802
- Locations
- 🇯🇵
University Hospital,Kyoto Prefectural University of Medicine ( Site 0012), Kyoto, Japan
🇯🇵Nagoya University Hospital ( Site 0003), Nagoya, Aichi, Japan
🇯🇵Sapporo Medical University Hospital ( Site 0002), Sapporo, Hokkaido, Japan